| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is fraught with obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. It's what we do. Best. |
Today's Rundown Lilly dumps phase 2 cancer drugs that survived previous cull In-demand Zymeworks nabs Seattle Genetics R&D executive Josephson European universities fail to report results for 83% of trials [Sponsored] Emerging Biotechs are Here to Stay; CROs Models Will Permanently Change After beefy funding rounds, exosome-focused Codiak guns for $86M IPO Alentis raises series A round to advance drug against novel liver disease target Vividion reels in $82M to push 3 lead programs toward the clinic AstraZeneca signs on BenevolentAI for lung, kidney drug discovery work Featured Story | | | Tuesday, April 30, 2019 Eli Lilly revealed in its first-quarter earnings presentation that it is dumping a PI3K/mTOR dual inhibitor it was developing for use in combinations and prexasertib, the CHK1 inhibitor it picked up from Array BioPharma. |
|
|
Top Stories Tuesday, April 30, 2019 Neil Josephson, former VP of clinical development at cancer biotech Seattle Genetics, has jumped ship to Zymeworks. Tuesday, April 30, 2019 The vast majority of universities are failing to comply with EU rules on the reporting of clinical trial results, according to a registry analysis. Monday, April 29, 2019 The prominence of emerging biotech looms large on the drug development landscape. CROs continue to adjust their core competencies and cultural mindset to tailor services for specific biotech needs. Tuesday, April 30, 2019 It’s had big names join its ranks and big backing from VCs; now, early-stage exosome biotech Codiak BioSciences wants in on the public market. Monday, April 29, 2019 Alentis Therapeutics has raised CHF 12.5 million ($12.2 million) to take an advanced liver disease drug toward clinical development. The series A tees a team led by ex-Ablynx CBO Markus Ewert up to advance a lead antibody against a previously undiscovered liver target. Tuesday, April 30, 2019 Vividion Therapeutics, a company looking to increase the number of proteins that small molecules can target, has raised $82 million to bring at least one of three programs through clinical proof of concept. Tuesday, April 30, 2019 AstraZeneca has tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at chronic kidney disease and idiopathic pulmonary fibrosis. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Elemental Machines Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”. Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA World Pharma Week June 17-20, 2019 | Seaport World Trade Center | Boston, MA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA 5th Annual CAR-TCR Summit September 10-13, 2019 | Boston, MA, USA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 